ClinVar Miner

Submissions for variant NM_000518.5(HBB):c.-79A>G (rs34598529)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Integrated Genetics/Laboratory Corporation of America RCV000020326 SCV000697149 pathogenic beta Thalassemia 2016-04-26 criteria provided, single submitter clinical testing Variant summary: The c.-79A>G variant affects a conserved nucleotide in TATA box in 5'UTR. One in-silico tool predicts damaging outcome for this variant. This variant is found in 2/5008 control chromosomes at a frequency of 0.0003994, which does not exceed maximal expected frequency of a pathogenic allele (0.0111803). In functional studies the variant of interest was shown to reduce the production of the b-globin mRNA. This change is a widely accepted to be deleterious and multiple clinical laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant was classified as pathogenic.
Fulgent Genetics,Fulgent Genetics RCV000763256 SCV000893893 pathogenic Beta-thalassemia, dominant inclusion body type; Fetal hemoglobin quantitative trait locus 1; Heinz body anemia; Hb SS disease; alpha Thalassemia; Susceptibility to malaria; beta Thalassemia; Methemoglobinemia, beta-globin type; Erythrocytosis 6, familial 2018-10-31 criteria provided, single submitter clinical testing
Invitae RCV000810653 SCV000950878 pathogenic not provided 2019-12-12 criteria provided, single submitter clinical testing This sequence change falls in the promoter of the HBB gene. It does not change the encoded amino acid sequence of the HBB protein, but has been reported to disrupt HBB transcription. This variant is present in population databases (rs34598529, gnomAD 0.3%). This variant has been observed in several individuals and families affected with mild beta thalassemia (PMID: 2123063, 6583702, 3021607, 28385923, 2458145). This variant is also known as c.-29A>G in the literature. ClinVar contains an entry for this variant (Variation ID: 15469). This sequence change, c.-79A>G, falls within the TATA box of the HBB gene and experimental studies have shown that this variant results in a reduction of B globin RNA compared to wild type HBB (PMID: 6583702). For these reasons, this variant has been classified as Pathogenic.
Myriad Women's Health, Inc. RCV000020326 SCV001194204 pathogenic beta Thalassemia 2019-10-18 criteria provided, single submitter clinical testing NM_000518.4(HBB):c.-79A>G(aka -29A>G) is classified as pathogenic and is associated with beta thalassemia. Sources cited for classification include the following: PMID: 2458145, and 6583702. Classification of NM_000518.4(HBB):c.-79A>G(aka -29A>G) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening.
OMIM RCV000016727 SCV000036997 pathogenic Beta-plus-thalassemia 1986-10-01 no assertion criteria provided literature only
GeneReviews RCV000020326 SCV000040702 pathogenic beta Thalassemia 2015-05-14 no assertion criteria provided literature only
The ITHANET community portal, The Cyprus Institute of Neurology and Genetics RCV000020326 SCV001244524 pathogenic beta Thalassemia 2019-11-25 no assertion criteria provided curation

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.